UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one‐stage clotting assays

Journal of thrombosis and haemostasis, 2019-01, Vol.17 (1), p.138-148

2019

Volltextzugriff (PDF)

A retrospective postlicensure survey of FEIBA efficacy and safety

Haemophilia : the official journal of the World Federation of Hemophilia, 2006-07, Vol.12 (4), p.352-362

2006

Volltextzugriff (PDF)

First report on the safety and efficacy of an extended half‐life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-09, Vol.23 (5), p.689-696

2017

Volltextzugriff (PDF)

Comparison of an automated chemiluminescent assay to a manual ELISA assay for determination of von Willebrand Factor collagen binding activity on VWD plasma patients previously diagnosed through molecular analysis of VWF

International journal of laboratory hematology, 2018-02, Vol.40 (1), p.77-83

2018

Volltextzugriff (PDF)

Contribution of genetic analysis in management of hemophilie patients

Archives de pédiatrie : organe officiel de la Société française de pédiatrie, 2010-06, Vol.17 (6), p.620-621

2010

Volltextzugriff (PDF)

Post-authorization safety study of Clottafact®, a triply secured fibrinogen concentrate in congenital afibrinogenemia. A prospective observational study

Vox sanguinis, 2016-11, Vol.111 (4), p.383-390

2016

Volltextzugriff (PDF)

Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-07, Vol.22 (4), p.e259-e266

2016

Volltextzugriff (PDF)

Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-09, Vol.19 (5), p.736-743

2013

Volltextzugriff (PDF)

Conception et suivi de l’implantation nationale de la formation HEMOPHAR, destinée aux pharmaciens d’officine prenant en charge des patients traités par emicizumab

Le Pharmacien Clinicien, 2022-12, Vol.57 (4), p.e129-e130

2022

Volltextzugriff (PDF)

Postauthorization safety study of Clottafact®, a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study

Vox sanguinis, 2018-02, Vol.113 (2), p.120-127

2018

Volltextzugriff (PDF)

Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels

Journal of thrombosis and haemostasis, 2013-06, Vol.11 (6), p.1043-1052

2013

Volltextzugriff (PDF)

Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-01, Vol.21 Suppl 1 (s1), p.1-12

2015

Volltextzugriff (PDF)

Recombinant activated factor VII in approved indications: Update on safety

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-07, Vol.24 (4), p.e275-e277

2018

Volltextzugriff (PDF)

SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-05, Vol.19 (3), p.e143-e150

2013

Volltextzugriff (PDF)

Consensus recommendations for the use of FEIBA® in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-03, Vol.19 (2), p.294-303

2013

Volltextzugriff (PDF)

FEIBA in the treatment of acquired haemophilia A: Results from the prospective multicentre French 'FEIBA dans l'hémophilie A acquise' (FEIBHAC) registry

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-05, Vol.21 (3), p.330-337

2015

Volltextzugriff (PDF)

Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey

Journal of thrombosis and haemostasis, 2004-07, Vol.2 (7), p.1096-1103

2004

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate

Journal of thrombosis and haemostasis, 2008-09, Vol.6 (9), p.1494-1499

2008

Volltextzugriff (PDF)

Reference center for platelet diseases

Archives de pédiatrie : organe officiel de la Société française de pédiatrie, 2007-06, Vol.14 (6), p.679-682

2007

Volltextzugriff (PDF)

Activated factor X cleaves factor VIII at arginine 562, limiting its cofactor efficiency

Journal of thrombosis and haemostasis, 2010-02, Vol.8 (2), p.286-293

2010

Volltextzugriff (PDF)

PERIOPERATIVE MANAGEMENT OF PATIENTS WITH HEMOPHILIA RECEIVING FITUSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC TARGETING ANTITHROMBIN FOR THE TREATMENT OF HEMOPHILIA

Hematology, Transfusion and Cell Therapy, 2020-11, Vol.42, p.74-75

2020

Volltextzugriff (PDF)

The potential role of synovial thrombomodulin in the pathophysiology of joint bleeds in haemophilia

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-09, Vol.18 (5), p.818-823

2012

Volltextzugriff (PDF)

Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-01, Vol.17 (1), p.e202-e210

2011

Volltextzugriff (PDF)

Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures

Thrombosis and haemostasis, 2000-05, Vol.83 (5), p.644-647

2000

Volltextzugriff (PDF)

1 – 25 von 837

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(715)
Mit Volltextzugriff
(678)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one‐stage clotting assays

La politique à l’épreuve des émotions

A retrospective postlicensure survey of FEIBA efficacy and safety

First report on the safety and efficacy of an extended half‐life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A

Comparison of an automated chemiluminescent assay to a manual ELISA assay for determination of von Willebrand Factor collagen binding activity on VWD plasma patients previously diagnosed through molecular analysis of VWF

Contribution of genetic analysis in management of hemophilie patients

Post-authorization safety study of Clottafact®, a triply secured fibrinogen concentrate in congenital afibrinogenemia. A prospective observational study

Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery

Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study

Conception et suivi de l’implantation nationale de la formation HEMOPHAR, destinée aux pharmaciens d’officine prenant en charge des patients traités par emicizumab

Postauthorization safety study of Clottafact®, a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study

Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels

Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014

Recombinant activated factor VII in approved indications: Update on safety

SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies

Consensus recommendations for the use of FEIBA® in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery

FEIBA in the treatment of acquired haemophilia A: Results from the prospective multicentre French 'FEIBA dans l'hémophilie A acquise' (FEIBHAC) registry

Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey

Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate

Reference center for platelet diseases

Activated factor X cleaves factor VIII at arginine 562, limiting its cofactor efficiency

PERIOPERATIVE MANAGEMENT OF PATIENTS WITH HEMOPHILIA RECEIVING FITUSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC TARGETING ANTITHROMBIN FOR THE TREATMENT OF HEMOPHILIA

The potential role of synovial thrombomodulin in the pathophysiology of joint bleeds in haemophilia

Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition

Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures

Suchergebnisse filtern